

THE LANCET Oncology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Martínez Chanzá N, Xie W, Bilen M A, et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. *Lancet Oncol* 2019; published online Feb 28. [http://dx.doi.org/10.1016/S1470-2045\(18\)30907-0](http://dx.doi.org/10.1016/S1470-2045(18)30907-0).

Appendix

Index:

1. Prior systemic therapies to cabozantinib.
2. Subsequent systemic therapies to cabozantinib.
3. Overall incidence of adverse events in patients who had dose reductions on cabozantinib.
4. List of participating centers.

1. Prior systemic therapies to cabozantinib

A total of 90 patients received cabozantinib as second line or beyond. The table details the systemic therapies received prior cabozantinib (more than one treatment was possible).

Prior treatment	Patients (N=90)
Sunitinib	39 (43%)
Pazopanib	29 (32%)
Axitinib	11 (12%)
Temsirolimus	8 (9%)
Everolimus	6 (7%)
Bevacizumab + Interferon-α	2 (2%)
Nivolumab	38 (42%)
Nivolumab + Ipilimumab	2 (2%)
Chemotherapy	13 (14%)
Clinical Trial / Other*	37 (41%)

Data are n (%). N=90. *The most frequent regimen was atezolizumab plus bevacizumab in 6 patients

2. Subsequent systemic therapies to cabozantinib

A total of 27 patients had data on subsequent systemic therapy after cabozantinib. The table shows the subsequent line of treatment received after cabozantinib.

Subsequent treatment	Patients (N=27)
Sunitinib	2 (7%)
Axitinib	3 (11%)
Everolimus	2 (7%)
Nivolumab	7 (26%)
Nivolumab + Ipilimumab	1 (4%)
Chemotherapy	1 (4%)
Clinical Trial / Other*	11 (41%)

Data are n (%). N=27. *The most frequent was lenvatinib plus everolimus in 5 patients

3. Overall incidence of adverse events in patients who had dose reductions on cabozantinib

A total of 51 patients required dose reductions because of treatment-related adverse events. The table details the overall incidence and grades of adverse events considered related to cabozantinib.

	Grade 1-2	Grade 3	Unknown grade
Diarrhoea	13 (26%)	2 (4%)	4 (8%)
Neutropenia	2 (4%)	0	0
Thrombocytopenia	5 (10%)	0	0
Fatigue	26 (51%)	1 (2%)	10 (20%)
Skin toxicity*	8 (16%)	5 (10%)	6 (12%)
Nausea	14 (27%)	0	5 (10%)
Vomiting	4 (8%)	0	3 (6%)
Hypertension	12 (24%)	3 (6%)	1 (2%)
Mucositis	8 (16%)	1 (2%)	5 (10%)
Dyspnoea	1 (2%)	0	2 (4%)
Hypothyroidism	8 (16%)	0	2 (4%)
Proteinuria	0	1 (2%)	1 (2%)
Transaminitis	15 (29%)	1 (2%)	1 (2%)

Data are n (%). N=51. Includes adverse events after the date of first dose and including 30 days after the date of last dose of cabozantinib. Patients with multiple events in the same category are counted only once in that category. Patients with events in more than one category are counted in each of those categories. No grade 4 or 5 adverse events were reported. *Skin toxicity included rash and palmar-plantar erythrodysesthesia.

3. List of participating centers

A list with all participating centers and their respective investigators as well as number of patients identified is provided. The list is organized in descending order according to the number of patients identified and earlier timing of contribution if the number of identified patients was equal.

- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. USA
PI: Nieves Martinez Chanza, Lauren C Harshman, Toni Choueiri, Dominick Bosse
Number of patients identified: 18
- Winship Cancer Institute, Emory University, Atlanta, GA. USA
PI: Mehmet Asim Bilen
Number of patients identified: 11
- Duke Cancer Center, Durham, NC. USA
PI: Hannah Dzimitrowicz and Michael R. Harrison
Number of patients identified: 9
- Department of Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH. USA
PI: Jarred Burkart and Amir Mortazavi
Number of patients identified: 8
- Fox Chase Cancer Center, Philadelphia, PA. USA
PI: Daniel M Geynisman and Elizabeth R Plimack

- Number of patients identified: 7
- Barbara Ann Karmanos Cancer Institute, Detroit, MI. USA
PI: Archana Balakrishnan and Ulka Vaishampayan
Number of patients identified: 7
 - University of Texas Southwestern Medical Center, Dallas, TX. USA
PI: I Alex Bowman and Hans Hammers
Number of patients identified: 6
 - Roswell Park Cancer Institute, Buffalo, NY. USA
PI: Rohit Jain and Saby George
Number of patients identified: 6
 - University of Chicago Comprehensive Cancer Center, Chicago, IL. USA
PI: Walter Stadler
Number of patients identified: 6
 - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA. USA
PI: Yousef Zakharia
Number of patients identified: 5
 - Abramson Cancer Center, Philadelphia, PA. USA
PI: Vivek Narayan and Naomi Haas
Number of patients identified: 5
 - Leuven Cancer Institute, UZ Leuven, Belgium.
PI: Benoit Beuselinck
Number of patients identified: 4
 - Moores Cancer Center, University of California San Diego, La Jolla, CA. USA
PI: Rana R. McKay
Number of patients identified: 3
 - Stephenson Cancer Center, Oklahoma City, OK. USA
PI: Abhishek Tripathi
Number of patients identified: 3
 - Washington University School of Medicine, St. Louis, MO. USA
PI: Russell Pachynski
Number of patients identified: 3
 - Huntsman Cancer Institute, Salt Lake City, UT. USA
PI: Andrew W. Hahn and Neeraj Agarwal
Number of patients identified: 2
 - City of Hope Comprehensive Cancer Center, Duarte, CA. USA
PI: JoAnn Hsu and Sumanta K Pal
Number of patients identified: 2
 - Stanford Cancer Institute, Palo Alto, CA. USA
PI: Sumit A. Shah, Sandy Srinivas
Number of patients identified: 2
 - University of Colorado Cancer Center, Aurora, CO. USA
PI: Elaine T. Lam

Number of patients identified: 2

- UNC Lineberger Cancer Comprehensive Center, Chapel Hill, NC. USA
PI: Tracy L Rose
Number of patients identified: 1

- Lifespan Cancer Institute, Alpert Medical School, Brown University, Providence, RI. USA
PI: Anthony E. Mega and Benedito A. Carneiro
Number of patients identified: 1

- Comprehensive Cancer Centers of Nevada, Las Vegas, NV. USA
PI: Nicholas Vogelzang
Number of patients identified: 1